# OnCo record gastric-msi-high (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gastric-msi-high/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gastric-msi-high" ;
  schema:name "Microsatellite-unstable (MSI-high) gastric cancer"@en ;
  schema:alternateName "MSI-H gastric cancer"@en, "Mismatch repair-deficient gastric cancer"@en, "dMMR gastric cancer"@en ;
  schema:description "Microsatellite-unstable gastric cancer has lost its DNA mismatch repair machinery, carries thousands of mutations and is unusually visible to the immune system. It responds strongly to checkpoint antibodies, may gain little from chemotherapy, and in early-stage disease immunotherapy before surgery is making many tumours disappear entirely."@en ;
  schema:url <https://onco.cc/cancers/gastric-msi-high/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Microsatellite_instability> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/31513484/>, <https://pubmed.ncbi.nlm.nih.gov/36179271/>, <https://en.wikipedia.org/wiki/Microsatellite_instability> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/checkmate-649/>, <https://onco.cc/trials/keynote-859/>, <https://onco.cc/terms/msi/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/gastrectomy/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/lynch-syndrome/> .